Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00726245

Plasma Rich in Growth Factors (PRGF) Treatment for Muscle Tear

PRP as a Treatment for Acute Muscle Tears - Randomized-double-blind-placebo Control Trail.

Sponsor: Meir Medical Center

Updated 5 times since 2017 Last updated: Jul 10, 2011 Started: Jan 31, 2008 Primary completion: Feb 28, 2009 Completion: Mar 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00726245, this PHASE2/PHASE3 trial focuses on Muscle Tear and remains completed. Sponsored by Meir Medical Center, it has been updated 5 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Meir Medical Center

Data source: Meir Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kfar Saba, Israel